Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Breast Neoplasms 8Neoplasm Metastasis 2Prostatic Neoplasms 1Neoplasms 1Melanoma 1HER2-positive Breast Cancer 1Exanthema 1Diarrhea 1Brest Cancer 1Breast Diseases 1Breast Cancer Metastatic 1Advanced/Metastatic Solid Tumors 1Advanced Breast Cancer 1

Interventions

Androgen Antagonists 10darolutamide 6Magnetic Resonance Spectroscopy 6apalutamide 5Docetaxel 5enzalutamide 4Specimen Handling 4Radiotherapy 4Radiosurgery 4Abiraterone Acetate 4Electroacupuncture 3Brachytherapy 3pembrolizumab 2bicalutamide 2Standard of Care 2Resistance Training 2Radiation 2Prednisone 2Pluvicto 2Interviews as Topic 2Gonadotropin-Releasing Hormone 2Glutamate Carboxypeptidase II 2Bone Density 2Absorptiometry, Photon 2testosterone 17 beta-cypionate 1relugolix 1perflutren 1olaparib 1luprolide acetate gel depot 1fluciclovine F-18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Prostatic Neoplasms × Fulvestrant × Clear all
NCT07570966 2026-05-06

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Not yet recruiting
217 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡